qpx7728
Small moleculeexperimental
Clinical trial activity
5 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 28, 2020 (NCT04380207)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- ADC-11INHIBITOR
ampC inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C(O)c1c(F)ccc2c1OB(O)[C@@H]1C[C@H]21- Mol. weight
- 221.98 g/mol
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4633785 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07104162 | Phase 1 | Sep 16, 2025 | Department of Health and Human Services, Orlando Clinical Research Center, Qpex Biopharma, Inc., Shionogi, University of Miami |
| NCT07083817 | Phase 1 | Aug 13, 2025 | Qpex Biopharma, Inc., Shionogi |
| NCT06547554 | Phase 1 | Sep 4, 2024 | Department of Health and Human Services, Qpex Biopharma, Inc., Shionogi |
| NCT05072444 | Phase 1 | Nov 15, 2021 | Department of Health and Human Services, Qpex Biopharma, Inc. |
| NCT04380207 | Phase 1 | Sep 28, 2020 | Department of Health and Human Services, Qpex Biopharma, Inc. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Qpex Biopharma, Inc. | For profit | 5 | 5 | 1 | 2020 |
| Department of Health and Human Services | Government | 4 | 0 | 1 | 2020 |
| Shionogi | For profit | 3 | 0 | 1 | 2024 |
| Orlando Clinical Research Center | For profit | 1 | 0 | 1 | 2025 |
| University of Miami | Academic/Hospital | 1 | 0 | 1 | 2025 |
5 organizations
Page 1 / 1